FRANKFURT: Germany's CureVac is on track to file for European approval of its COVID-19 vaccine as early as this month because high infection rates among trial participants are bringing a read-out on efficacy within closer reach.Advertisement
But more volumes will be needed to boost lagging immunisation coverage in Europe and potentially for repeated booster shots. Current infection rates in participating country Peru, in particular, have put CureVac well on track to meet its timetable, Haas said. For the trial read-out expected later this month, CureVac will publish details on its primary goal of preventing COVID-19 across all virus variants.
Singapore Latest News, Singapore Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.